Genentech Announces Manufacturing Expansion in Hillsboro, Oregon
Genentech to Invest $750 Million in New Device Fill-Finish Manufacturing Facility in Oregon Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), has announced plans to invest…
Integrated DNA Technologies Advances DNA Synthesis with Expanded Speed, Complexity and Scale
Integrated DNA Technologies Expands DNA Synthesis Capabilities to Support Genomics Programs Across Scale and Complexity Integrated DNA Technologies (IDT), a Danaher company and global provider of genomics solutions, has announced…
bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective August 24, 2026
bioAffinity Technologies Announces 1-for-15 Reverse Stock Split to Support Nasdaq Compliance bioAffinity Technologies, Inc., a biotechnology company developing noninvasive technologies for the detection of early-stage cancer, has announced that it…
Charles River and Medigen Partner to Advance Vaccine Development Using Next-Generation Sequencing
Charles River Laboratories and Medigen Vaccine Biologics Collaborate to Advance Next-Generation Multivalent Enterovirus Vaccine Charles River Laboratories and Medigen Vaccine Biologics Corp. (MVC) have entered into a strategic collaboration focused…
Mitochon Pharmaceuticals Receives $1 Million ALS Association Award for Phase II Clinical Study
Mitochon Pharmaceuticals Receives $1 Million ALS Association Award to Advance MP-101 Clinical Development Mitochon Pharmaceuticals has announced that it has received a $1 million Hoffman ALS Clinical Trial Award from…
Complete Genomics Appoints Lauren Selig to Board of Directors
Complete Genomics Appoints Entrepreneur and Investor Lauren Selig to Board of Directors Complete Genomics, a U.S.-based company specializing in end-to-end DNA sequencing platforms, reagents, and software, has announced the appointment…
NTx Bio Supports Baylor College of Medicine in Manufacturing Personalized Cancer Vaccine for Phase 1 Melanoma Trial
NTx Bio Platform Supports Personalized mRNA Vaccine Manufacturing for Phase 1 Melanoma Trial NTx Bio, a company developing next-generation biomanufacturing technologies, announced that its NTxscribe® CORE platform is being used…
Tolerance Bio Licenses Efineptakin Alfa from NeoImmuneTech to Advance Immune Resilience Programs
Tolerance Bio Licenses Efineptakin Alfa From NeoImmuneTech to Advance Thymus-Targeted Therapies Tolerance Bio, Inc., a biotechnology company focused on preserving, regenerating, and modulating thymic function to address immune-related diseases and…
Regenerative Research Foundation Wins NIH’s Complement-ARIE Challenge
Regenerative Research Foundation Selected as a Winner of NIH’s Complement-ARIE Challenge The Regenerative Research Foundation has announced that its Neural Stem Cell Institute (NSCI) has been selected as a Phase…
Merck and Moderna Report Positive Phase 3 INTerpath-001 Results in Resected Melanoma
Merck and Moderna Report Positive Phase 3 Results for Personalized mRNA Cancer Therapy in Melanoma Merck, known as MSD outside the United States and Canada, and Moderna, Inc. have announced…
BioTalent Canada and Montréal InVivo Partner to Strengthen Quebec’s Life Sciences Workforce
BioTalent Canada and Montréal InVivo Strengthen Partnership to Expand Life Sciences Workforce Development BioTalent Canada and Montréal InVivo have announced an expanded partnership designed to strengthen workforce development across Canada’s…
BeOne Medicines Renews Partnership to Expand BRUKINSA® Access in Low- and Middle-Income Countries
BeOne Medicines, BeOne Care Foundation and The Max Foundation Renew Partnership to Expand BRUKINSA Access for Patients With CLL BeOne Medicines Ltd., a global oncology company, has announced the renewal…